Indapamide 吲达帕胺
CAS 26807-65-8 MFCD00079375
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Alphabetic, Analytical Standards, Analytical/Chromatography, Chemical Structure, Chromatography, Diuretic, Doping Substances, Drugs & Metabolites, Drugs of Abuse, Forensic and Veterinary Standards, I, Neat Compounds, Others
- {SNA} All Doping Standards (A-Z), Alphabetic, Analytical Standards, Analytical/Chromatography, Chemical Structure, Chromatography, Diuretic, Doping Substances, Drugs & Metabolites, Drugs of Abuse, Forensic and Veterinary Standards, I,
产品应用
- Used as an antihypertensive. Diuretic.
相关文献及参考
- Leary, et al.: Curr. Ther. Res., 15, 571 (1973),
- Kyncl, J., et al.: Arzneim.-Forsch., 25, 1491 (1975),
- DiFeo, T.J., et al.: Anal. Profiles Drug Subs. Excip., 23, 229 (1994),
- Merck 14 ,4935
安全信息
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 347 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 25,1491,1975
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : >3 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year:
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >3 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 25,1491,1975
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 272 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 25,1491,1975
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 110 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 10,1337,1982
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 1100 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 10,1337,1982
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE : 260 mg/kg SEX/DURATIO
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 270 mg/kg SEX/DURATION : female 17-22 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 10,1363,1982
其他信息
- MSDS 信息:N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline(26807-65-8).msds
- 储运特性:库房通风低温干燥
- 急性毒性:口服-大鼠LD50: >;3000 毫克/公斤; 口服-小鼠LD50: >;3000 毫克/公斤
- 毒性分级:中毒
- MOL 文件:26807-65-8.mol
- 灭火剂:干粉、泡沫、砂土、二氧化碳, 雾状水
- 利尿降压药:白色针状结晶或结晶性粉末,无臭,无味。几乎不溶于水或稀盐酸,溶于乙醇或醋酸乙酯,易溶于丙酮、冰醋酸,微溶于氯仿或乙醚。 吲达帕胺是目前国内常用的一种非处方类利尿降压药,具有疗效好,降压平稳,副反应少等优点,最初由法国施维雅(Servier)制药公司首次研发开发,我国在1988年由天津力生制药首次成功开发了吲达帕胺薄膜衣片,商品名为“寿比山”。20世纪90年代中期,浙江普洛康裕制药、烟台西苑制药厂、浙江东日药业、东莞万成制药、山西亚宝药业、阜新芝田药业、濮阳汇元药业、重庆药友制药8家药厂获准生产制剂。90年代末,法国施维雅制药公司将吲达帕胺缓释片剂引入国内,商品名为“纳催离”。随后,吲达帕胺原料药国产化有了推进,目前国内有7家企业获准生产原料药品种。 吲达帕胺具有利尿和钙拮抗双重作用,通过抑制远曲小管近端的Na+重吸收,产生利尿作用,又阻滞Ca2+内流,对血管平滑肌有较高选择性,使外周小血管扩张,产生降压作用。但对血管平滑肌作用强于利尿作用,低于利尿剂量时即可降压,较高剂量时显示利尿作用,但无噻嗪类利尿药的缺点,即不引起体位性低血压、潮红和反射性心动过速,对血象、血脂、糖代谢及肾功能也无明显影响,治疗剂量对心率、心输出量、心电图均无明显改变,对中枢神经系统和植物神经无明显作用。口服2~3h产生降压效应,作用维持24h,单独用药效果良好。利尿作用3h出现,4~6h达最大效应。与其他利尿剂不同,本品脂溶性高,口服吸收后,在肝、肾血浆浓度最高,心、肺、肌肉、脂肪中浓度较低。本品主要以代谢产物和以5%的原型从肾脏排泄。吲达帕胺适用于轻、中度原发性高血压,亦可用于充血性心力衰竭引起的水钠潴留,对伴有肾衰、糖尿病、高血脂的高血压患者也适用,单用降压效果显著,与β受体阻滞剂合用疗效更佳,因为本药有利尿作用,可引起低血钾,可同时补充钾盐。
- 可燃性危险特性:可燃;燃烧产生有毒氮氧化物, 硫氧化物和氯化物烟雾
- 用途一:用于轻、中度原发性高血压。
- Sigma Aldrich:26807-65-8(sigmaaldrich)
- 类别:有毒物品